Researchers at the George Washington University (GW) found that certain symptoms are more and less predictive of patients’ risk for acute coronary syndrome (ACS), which includes heart attack, in patients of different gender and race.

BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions, June 14-17 in New Orleans. The study found chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can be treated safely and effectively with Ekos therapy. The ACCESS PTS protocol using Ekos therapy is now the only treatment regimen proven to significantly reduce the signs and symptoms of PTS and show a significant improvement in quality of life, according to the company.

Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper from the European Society of Cardiology published in the June issue of European Heart Journal - Cardiovascular Pharmacotherapy.

July 6, 2017 — New data showed use of Medtronic’s cardiac resynchronization therapy (CRT) devices with its proprietary AdaptivCRT and EffectiveCRT algorithms results in lower healthcare system costs, and improves therapy delivery in heart failure patients who also have atrial fibrillation (AF). The results of three analyses were presented at the European Heart Rhythm Association (EHRA) EUROPACE-CARDIOSTIM 2017, June 18-21 in Vienna, Austria.

GE Additive and Stryker have entered a partnership agreement to support Stryker’s growth in additive manufacturing. The agreement covers new additive machines, materials and services for Stryker’s global supply chain operations. The announcement was made at GE’s Minds + Machines event, the company’s industrial internet event dedicated to software, innovation and the sharing of digital industrial outcomes.

Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter defibrillator (ICD), suggests a new study published in the Journal of the American College of Cardiology. According to the researchers, confirming the findings in a larger, randomized trial could lead to new national guidelines for choosing patients who are good candidates for ICD implantation.

Women and physicians do not put enough emphasis on cardiovascular disease in women, and a social stigma regarding body weight may be a primary barrier to these important discussions, according to new research. The findings were published in the Journal of the American College of Cardiology.

July 6, 2017 — GE Healthcare and HeartFlow Inc. announced at the annual scientific meeting of the Society of Cardiovascular Computed Tomography (SCCT), that they have entered into a global collaboration agreement with the goal of increasing the clinical availability and adoption of HeartFlow fractional flow reserve computed tomography (FFR-CT), a proprietary technology that helps clinicians diagnose and treat patients with suspected coronary artery disease (CAD).

Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH). All enrolled patients were being treated with a Phosphodiesterase-5 inhibitors (PDE-5 inhibitors), either as monotherapy or in combination with an endothelin receptor antagonist (ERA), and who did not reach their therapeutic goal. The study, which is a part of the collaboration between Bayer and Merck, is seeking to enroll patients at 26 sites in the United States with a total of 100 study sites worldwide.

Michigan Medicine recently became the first healthcare institution in the United States to install the Artis pheno, the new robotic C-arm angiography system from Siemens Healthineers. The system is designed to broaden clinical capabilities and expand patient access while combating patient infection.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now